Idiopathic pulmonary fibrosis
Drug Safety Update
November 2020: Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing
July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
NICE guidance (see drug-specific links below)
CG163: Idiopathic pulmonary fibrosis in adults: diagnosis and management, June 2013 (last updated May 2017)
These drugs are available from specialist centres only and should be initiated and supervised by an appropriate specialist
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary